Analyzing cancer biomarkers and mutations for targeted therapy
Integrated Molecular Analysis of Cancer (IMAC)
This study is trying to find specific genetic markers in cancer patients' tumors to see if matching these markers with targeted treatments can improve their outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1800 (estimated) |
| Ages | 21 Years and up |
| Sex | Female |
| Sponsor | National University Hospital, Singapore Academic / other |
| Locations | 1 site (Singapore) |
| Trial ID | NCT02078544 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify biomarkers and actionable mutations in cancer patients by analyzing tumor samples. It hypothesizes that molecular profiling can enhance treatment outcomes with targeted therapies and provide insights into drug resistance and metastasis. By systematically sequencing cancer genomes, the study seeks to match patients with specific genetic aberrations to appropriate therapeutic strategies. The goal is to optimize personalized cancer medicine through detailed molecular analysis.
Who should consider this trial
Good fit: Ideal candidates include patients aged 21 and older with histologically confirmed cancers who are eligible for systemic therapy, including biomarker-driven clinical trials.
Not a fit: Patients who are unable to provide informed consent or do not have sufficient tumor tissue for molecular profiling may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective, personalized treatment options for cancer patients based on their unique molecular profiles.
How similar studies have performed: Other studies have shown success in using molecular profiling to guide targeted cancer therapies, indicating a promising approach in this field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with histological confirmation of cancers who are candidates for systemic therapy, including molecular-targeted therapy/ biomarker-driven clinical trials. 2. Patients must be ≥ 21 years old. 3. All patients must have signed and dated an informed consent form. 4. All patients must have sufficient tumour tissue for molecular profiling Exclusion Criteria: Unable to provide informed consent
Where this trial is running
Singapore
- David Tan Shao Peng — Singapore, Singapore (Recruiting)
Study contacts
- Study coordinator: Shao peng David Tan, MBBS, MRCP, PHD
- Email: david_sp_tan@nuhs.edu.sg
- Phone: (65) 6779 5555
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.